Drug Profile
Research programme: glycosylated antibodies - GlycoFi/Dartmouth
Latest Information Update: 25 Mar 2008
Price :
$50
*
At a glance
- Originator Dartmouth College; GlycoFi
- Developer GlycoFi
- Class
- Mechanism of Action CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Mar 2008 Discontinued - Preclinical for Cancer in Lebanon (unspecified route)
- 25 Mar 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 23 Jan 2006 Preclinical trials in Cancer in Lebanon (unspecified route)